Oculis (NASDAQ:OCS) Shares Gap Up – Here’s What Happened

Oculis Holding AG (NASDAQ:OCS) shares gapped up before the market opened on Wednesday . The stock had previously closed at $15.37, but opened at $15.89. Oculis shares last traded at $15.89, with a volume of 316 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Oculis in a report on Monday, November 11th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $29.20.

Oculis Trading Up 3.4 %

The firm has a market capitalization of $643.55 million, a P/E ratio of -7.96 and a beta of -0.34. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02. The firm has a 50 day simple moving average of $15.09 and a two-hundred day simple moving average of $12.95.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.